Hier mal eine ganz schöne Übersicht aus dem ihub:
SNTA KEY DD..MUST READ:
Total cash, cash equivalents and marketable securities is $90M. Cash for cash pps should be 0.66. Read article here:
www.bizjournals.com/boston/blog/bioflash/...han.html?ana=yahoo
"Synta Pharmaceuticals Corp. currently has an average rating of “Hold” and a consensus price target of $2.56."
www.wkrb13.com/markets/1144940/...ased-by-jennison-associates/
SNTA overdue for a bounce:
www.insiderfinancial.com/...asdaqsnta-due-for-a-bounce/114352/
In early 2013 SNTA pps was $12! In 2008 GlaxoSmithKline struck a $885M deal with SNTA.
ir.syntapharma.com/...88&p=irol-newsArticle&ID=1235544
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
www.newsoracle.com/...m-synta-pharmaceuticals-corp-snta/35332/
One failed trial and the pps got crushed. The 6 primary end results for 6 different cancer indications are due within the next 6-7 months! They have been 6 years in the testing:
SNTA phase I/II/III upcoming catalysts.
Mesothelioma (started in Apr 2012) trial results overdue now (Feb 2016):
clinicaltrials.gov/ct2/show/NCT01590160
As are Eclesclomol (started in Apr 2009) for Ovarian Cancer (were due January 2016):
clinicaltrials.gov/ct2/show/NCT00888615
And in May 2016 Breast Cancer trial results are due:
www.syntapharma.com/clinical-trials-breast-cancer.php
In July 2016 Melanoma (started in Sept 2010) trial results are due:
clinicaltrials.gov/ct2/show/NCT01200238
In September 2016 another Ovarian Cancer (started in Oct 2013) trial results are due:
clinicaltrials.gov/ct2/show/NCT01962948
In October 2016 Small Cell Lung Cancer (started in Oct 2014) trial results are due:
clinicaltrials.gov/ct2/show/NCT02261805
137M O/S..
49.2% institutional ownership:
www.nasdaq.com/symbol/snta/institutional-holdings
-Directors own 11% of the O/S (14M)
-Leaves FLOAT of just 55M!!
10 different cancer indications:
Breast Cancer
Acute Myeloid Leukemia
Ovarian Cancer
Colon/Rectal Cancer
Malignant Peripheral Nerve Sheath Tumors
Mesothelioma
Multiple Myeloma
Ocular Melanoma
Small Cell Lung Cancer
Solid Tumors
www.syntapharma.com/clinical-trials.php
29 clinical trials ongoing...29!!
Huge institutional names own SNTA including:
Morgan Stanley
Goldman Sachs
BNP ParisBas
Charles Schwab
BlackRock
Deutsche Bank
Wells Fargo
Credit Suisse
CitiGroup
Royal Bank of Canada
Vanguard Group
Caxton Corp
Jacobs Levy
Barclays PLC
Swiss National Bank
Jacobs Levy
Panagora
Nomura Holdings
...and many more!
www.nasdaq.com/symbol/snta/institutional-holdings
Zurück
